Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia

• Published in: Clinical cancer research Vol. 26; no. 23; pp. 6187 - 6195
• Main Authors: Thangavadivel, Shanmugapriya, Zhao, Qiuhong, Epperla, Narendranath, Rike, Lindsey, Mo, Xiaokui, Badawi, Mohamed, Bystry, Darlene M, Phelps, Mitch A, Andritsos, Leslie A, Rogers, Kerry A, Jones, Jeffrey, Woyach, Jennifer A, Byrd, John C, Awan, Farrukh T
• Format: Journal Article
• Language: English
• Published: United States 01.12.2020
• Subjects: Adult; Aged; Angiogenesis Inhibitors - therapeutic use; Female; Follow-Up Studies; Humans; Lenalidomide - therapeutic use; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Male; Middle Aged; Prognosis; Survival Rate
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-20-1280

Infectious complications constitute a leading cause of morbidity and mortality in chronic lymphocytic leukemia (CLL). Patients respond poorly to vaccines, particularly pneumococcal polysaccharide and influenza vaccines. In addition, patients with genetically high-risk disease are at increased risk for early disease progression and death. Lenalidomide, an oral immunomodulatory agent with demonstrated clinical activity in CLL, can potentially restore immune system dysfunction associated with CLL while improving disease outcomes. Phase II study randomized 49 patients with genetically high-risk CLL or small lymphocytic lymphoma [SLL; defined as unmutated Ig heavy chain variable region, deletion(17p) or (11q), and/or complex abnormal karyotype], to receive lenalidomide either concurrent (arm A) or sequential to (arm B) two doses of 13-valent protein-conjugated pneumococcal vaccine (PCV13) administered 2 months apart, in patients not meeting International Workshop on Chronic Lymphocytic Leukemia treatment criteria. Four serotypes (3, 4, 5, 6B) achieved the additional seroprotection definition of a fourfold increase in arm A, and six serotypes (3, 4, 5, 6B, 19A, 19F) in arm B. All patients achieved the defined concentration of 0.35 μg/mL for at least one serotype tested. No significant difference was observed with the addition of lenalidomide. At median time on treatment of 3.6 years, median progression-free survival (PFS) was 5.8 years [95% confidence interval (CI), 3.1-not reached]. PFS at 1, 2, and 3 years was 85% (95% CI, 72-93), 79% (95% CI, 64-88), and 72% (95% CI, 57-83), respectively. Lenalidomide is efficacious with manageable toxicities as an early intervention strategy in patients with high-risk CLL, but did not enhance humoral response to PCV13 vaccine.